TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Three Drug Combinations for Intermittent Treatment of Malaria in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 1 to 5 years at enrolment.~2. Informed consent obtained from parents or legal guardians.~3. No current participation in another malaria intervention trial.~4. Free of obvious health problems as established by medical history and clinical examination before entering into the study.~5. Available for the duration of the study.~Exclusion Criteria:~1. Known allergy to any of the antimalarial drugs used in the trial and if this is unknown, then a history of allergic reaction to any drug.~2. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory tests.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): SP+AQ
- 2 (Type: EXPERIMENTAL): Piperaquine plus SP arm
- 3 (Type: EXPERIMENTAL): Du-Cotecxin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* HbA1c of 6.8% to 10.0%, inclusive.~* Body mass index (BMI) of 25 kg/m\^2 to 40 kg/m\^2, inclusive.~Exclusion Criteria:~* Have participated in this study previously, or have received exenatide, pramlintide acetate, GLP-1 analogs, or dipeptidyl peptidase-IV (DPP-IV) inhibitors~* Have participated in an interventional, medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment was given) within 30 days of study start. This criterion includes drugs that have not received regulatory approval for any indication at the time of study start.~* Treated with any of the following medications:~  * Thiazolidinedione within 5 months of screening;~ * Sulfonylurea within 3 months of screening;~ * Metformin/sulfonylurea combination therapy within 3 months of screening;~ * Alpha-glucosidase inhibitor within 3 months of screening;~ * Meglitinide within 3 months of screening;~ * Insulin for more than 1 week within the 3 months prior to screening.~ * Symlin (pramlintide acetate) injection or Byetta (exenatide) injection at any time~ * Chronic (more than 2 weeks) or recent (within 4 weeks of study start) use of a drug that directly affects gastrointestinal motility~ * Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within the 4 weeks immediately preceding study start~ * Regular use of a medication with addictive potential such as an opiate, narcotic, or tranquilizer~ * Systemic antineoplastic agent~ * Systemic transplantation medication~ * Drugs for weight loss, including over-the-counter medications, within the 4 months prior to study start

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide Arm (Type: EXPERIMENTAL): None
- Exenatide plus Rosiglitazone Arm (Type: EXPERIMENTAL): None
- Rosiglitazone Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Ages 4 through 26 years, inclusive~* Clinical history of allergy to peanuts or peanut-containing foods~* Serum IgE to peanut \>0.35 kU/L (determined by UniCAP within the past 12 months) and/or a SPT to peanut \>3 mm compared to control~* Experience dose-limiting symptoms at or before the 100mg dose of peanut protein (measured as 200 mg of peanut flour) on abbreviated screening OFC conducted via PRACTALL guidelines~* Use of birth control by females of child-bearing potential~Key Exclusion Criteria:~* History of Cardiovascular disease~* History of frequent or repeated, severe or life-threatening episodes of anaphylactic shock~* History of other chronic disease~* History of eosinophilic gastrointestinal disease~* Severe asthma~* Mild or moderate asthma if uncontrolled~* Use of omalizumab within the past 6 months or current use of other non-traditional forms of allergen immunotherapy~* Use of beta-blockers(oral), angiotensin-converting enzyme (ACE)~* Pregnancy, lactation~* Having the same place of residence as another study subject~* Participation in an interventional clinical trial 30 days prior to randomization

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 26 Years
- Healthy Volunteers: f

Study Arms:
- AR101 powder provided in capsules (Type: EXPERIMENTAL): Study product provided as peanut protein in pull-apart capsules
- Placebo powder provided in capsules (Type: PLACEBO_COMPARATOR): Placebo formulation in pull-apart capsules containing only inactive ingredients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~- Must be 18 years of age or older.~Have a score of 6 or greater on the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis at and/or prior to Screening Visit.~* Have ≥4 tender/painful joints on motion and ≥4 swollen joints (28 joint counts) at both Screening Visit and Baseline Visit (Visit 1).~* Have moderate to severe disease activity as defined by CDAI\>10 and DAS28-4(ESR) ≥3.2 at Baseline Visit.~* Have taken an oral MTX treatment regimen (15-25mg/week) continuously for at least 4 months prior to the screening visit and has taken a stable weekly dose of oral MTX with supplemental folic acid or folinic acid for at least 4 weeks prior to the baseline visit (conversion from parenteral MTX to oral MTX will require stabilization of the treatment regimen for at least 1 month).~* Subjects must screen negative for active tuberculosis or inadequately treated tuberculosis infection (active or latent).~Key Exclusion Criteria~* Pregnant female subjects; breastfeeding female subjects; male subjects with partners currently pregnant; male subjects able to father children and female subjects of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception as outlined in this protocol for the duration of the study and for at least 3 months after the last dose of investigational product.~* Subjects with infection or infection history; subjects with any current malignancy or a history of malignancy (except adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ); subjects with history of, or current evidence for, severe gastrointestinal narrowing (pathologic or iatrogenic); and subjects with history of documented diverticulitis.~* Subjects with a history of insufficient response to ≥2 biologics, regardless of the class.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CP-690,550 and methotrexate (Type: EXPERIMENTAL): Open-label tofacitinib tablet and blinded methotrexate capsule
- CP-690,550 and placebo (Type: PLACEBO_COMPARATOR): open-label tofacitinib tablet and blinded matching placebo for methotrexate capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Apelin on Insulin Sensitivity: Proof of Concept in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men aged 18 to 40 years.~* BMI between 25 and 30 kg / cm ² (excluding terminals).~* Free of known chronic disease and any medication (any medication within 30 days prior to the inclusion visit).~* Non-pathological ECG.~* Heart rate between 50 and 80 beats per minute rest.~* Complete Blood Count (CBC) with no significant anomaly in terms of the investigator.~* Liver function tests without clinically significant abnormalities in terms of the investigator.~* Renal function tests without clinically significant abnormalities in terms of the investigator.~* Serum electrolytes without clinically significant abnormalities in terms of the investigator.~* Fasting plasma glucose less than 1.1 g / l.~* HbA1c within the normal range (4-6%).~* Good peripheral vein (forearm and back of the hand).~* Agreement to participate in the establishment of a serum bank.~* Sedentary or practicing occasional physical activity.~* Ability to sign informed consent.~* Affiliation to a social security scheme.~Exclusion Criteria:~* Risk factor, treatment or ECG as recommended by International Conference on Harmonization E14 (ICH E14) Clinical Evaluation of QT / corrected QT interval (QTc Interval= Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs~* Repeated a QTc interval\> 450 ms measurement~* Risk factor: myocardial infarction, hypokalemia, family history of long QT syndrome~* Personal history of cancer.~* Positive HIV serology.~* Hepatitis B serology positive.~* Positive hepatitis C serology.~* Cognitive impairment or mental illness (at the discretion of the investigator).~* Chronic excessive alcohol consumption (consumption\> 30g/jour or 210g/week).~* Person under judicial protection, guardianship.~* Subject with a resting systolic blood pressure greater than 140 mm Hg and diastolic blood pressure greater than 90 mmHg~* Smoking\> 10 cig / day and can not be interrupted for 24 hours.~* Subject exclusion period of another protocol.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Apelin (Type: EXPERIMENTAL): An apelin clamp in which an apelin infusion will be administered prior to reference clamp
- Placebo (Type: PLACEBO_COMPARATOR): A clamp reference during which a placebo solution (saline solution) will be administered prior to apelin clamp

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants (outpatients) between the regional age of majority (18 or 19 years of age) to 65 years of age, inclusive, at the time of informed consent.~* Primary diagnosis of MDD and in a current non-psychotic major depressive episode (MDE) as defined by Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria, who have been outpatients for at least 4 weeks, and have an inadequate response, per investigator judgment, to 1 or 2 adequate treatments of ADTs in their current MDE, including current ADT.~* Participants with a Patient Health Questionnaire 9-item scale (PHQ-9) ≥ 15 at the screening and baseline visits, if separate.~Exclusion Criteria:~* Participants currently or previously treated with brexpiprazole including participants who received brexpiprazole in any prior clinical trial.~* Participants with a concurrent DSM-5 diagnosis of the following will be excluded:~  * Schizophrenia or schizoaffective disorder~ * Bipolar I or bipolar II disorder~ * Post-traumatic stress disorder~ * Dementia~ * Eating disorder~ * Borderline personality disorder~ * Antisocial personality disorder~* Participants with a suicidality score of 3 based on Inventory of Depressive Symptomatology Self-Report (IDS-SR) suicidality item 18 or participants who, in the opinion of the investigator, presents a serious risk of suicide.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole (Type: OTHER): Participants received brexpiprazole as a flexible dose; 0.5 mg to 2 mg, orally (PO), QD, and continued on the stable dose of ADT up to 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of cystic fibrosis (CF) and G551D mutation in at least 1 allele~* Forced expiratory volume in 1 second (FEV1) of 40% to 90% (inclusive) of predicted normal for age, gender, and height at Screening.~* No clinically significant abnormalities that would have interfered with the study assessments, as judged by the investigator~* Willing to use highly effective birth control methods during the study~Exclusion Criteria:~* History of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject~* Acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks of Day 1 of the study~* History of alcohol, medication or illicit drug abuse within one year prior to Day 1~* Abnormal liver function ≥ 3x the upper limit of normal~* Abnormal renal function at Screening~* History of solid organ or hematological transplantation~* Pregnant, planning a pregnancy, breast-feeding, or unwilling to follow contraception requirements~* Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days prior to Screening~* Use of inhaled hypertonic saline treatment~* Concomitant use of any inhibitors or inducers of cytochrome P450 3A4 (CYP 3A4)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects who received placebo every 12 hours (q12h) for up to 48 weeks.
- 150 mg Ivacaftor q12h (Type: EXPERIMENTAL): Subjects who received 150 mg of ivacaftor q12h for up to 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~(1) Unlimited gender, aged 18-75 years; (2) Meets American Association for the Study of Liver Diseases (AASLD) or European Association for the Study of the Liver (EASL) clinical diagnostic criteria of hepatocellular carcinoma; (3) Barcelona Clinic Liver Cancer (BCLC) Stage B or C, and there is at least one measurable tumor in the liver (long diameter ≥ 1cm);(4) progressing after standard treatment; (5) Unresponsive or resistant to Lenvatinib; (6) Child-Pugh A or scored 7 B; (7) Eastern Cooperative Oncology Group performance status score \<= 1; (8) Platelet count \>= 60x10\^9/L, Prothrombin time prolonged \<= 6 seconds.~Exclusion Criteria:~(1) Uncorrectable coagulopathy with obvious bleeding tendency; (2) Patients need long-term anticoagulant or anti platelet therapy and cannot stop the drugs; (3) Patients with unstable or active ulcer or gastrointestinal bleeding; (4) Heart disease requiring treatment or not well controlled high blood pressure; (5) Patients with interstitial pneumonia; (6) Hepatic encephalopathy or refractory ascites requiring treatment; (7) There is a clear active infection; (8) Receiving radiotherapy/chemotherapy/interventional therapy for tumor within 4 weeks before the start of the study; (9) Severe insufficiency of important organs, such as severe cardiopulmonary insufficiency; (10) Other accompanying anti-tumor treatments; (11) The investigator assessed that the patient was unable or unwilling to comply with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Combination therapy with Lenvatinib and Gefitinib (Type: EXPERIMENTAL): First week: Gefitinib 125mg/day, Lenvatinib 8mg/day if body weight ≤ 60Kg and 12mg/day if body weight \> 60Kg. If the patient is well tolerated, the dose of Gefitinib will be adjusted to 250 mg/day after one week, and the dose of Lenvatinib will remain the same (8mg/day for weight ≤ 60Kg and 12mg/day for weight \> 60Kg). Route of administration: Oral.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Articaine vs Dexmedetomidine Supplemented Articaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patient with chronic renal failure on hemodialysis scheduled for radiocephalic fistula creation~Exclusion Criteria:~* Allergy to local anesthetics.~* Infection at the site of needle insertion.~* Those having international normalized ratio more than 1.5.~* Coagulopathy.~* Neuromuscular, or severe hepatic or severe pulmonary disease.~* Those having epilepsy.~* Patients who refused to participate.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): Patients received ultrasound guided supraclavicular block with 40 ml of Articaine hydrochloride 2%
- Group AD (Type: EXPERIMENTAL): Patients received ultrasound guided supraclavicular block with 40 ml articaine 2% mixed with dexmedetomidine (1 µg/kg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, unmarried females age 16 to 23 years with intact uteri~* Not pregnant at enrollment~* Agreed to use effective contraception through Month 7 of the study~* A lifetime history of 0 to 5 male partners with whom the subjects engaged in at least one episode of insertive intercourse~Exclusion Criteria:~* No prior history of Human Papillomavirus (HPV) vaccination~* No receipt of any other vaccination within 1 month prior to enrollment or plans to receive any other vaccination within 1 month prior to or after any dose of study vaccine~* No prior history of an abnormal Papanicolaou (Pap) test showing Squamous intraepithelial lesion (SIL) or biopsy showing Cervical intraepithelial neoplasia (CIN)

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 23 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): HPV 16 L1 VLP vaccine
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Traditional Persian Medicine Preparation Versus Artificial Saliva for Radiation Induced Xerostomia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with head and neck cancer who had grade 1 and 2 xerostomia (based on the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0) and finished radiotherapy at least two months before the study(22).~Exclusion Criteria:~* history of connective tissue disorder (e.g., Sjogren) other medical causes of xerostomia (such as diabetes, bowel and renal diseases), using antidepressants drugs, recurrence of cancer, end stage cancer, pregnancy, lactation history of hypersensitivity or allergy to A. digitata and M. sylvestris

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- control (Type: ACTIVE_COMPARATOR): In the control group, patients received Hypozalix (artificial saliva)spray three times per day for a period of four weeks.
- intervention (Type: EXPERIMENTAL): Patients in intervention group received sachets containing 4 grams of mixed powder of A. digitata and M. sylvestris (in a proportion of 1:1), three times per day for a period of four weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete